APPLICATIONS
- A preclinical model to assess single or multi-agent therapies for lymphomas (cutaneous T-cell lymphoma cell lines, B-cell lymphoma cell lines and PDX model)
- A robust, reproducible and quick (15 days) model for in vivo drug testing
- Preclinical evaluation of cutaneous lymphoma proliferation, tumor growth and migration
DESCRIPTION
- Original method of intrahepatic injection of CTCL into adult immunodeficient mice
- Engraftment validated with aggressive (My-La, HUT78, HH, MAC2A, MAC2B) and indolent (FE-PD, MAC1) CTCL cell lines, DLBCL cell line (HLY1) and patient-derived CTCL xenograft
- Migration and cell spreading assessment in blood, kidneys, lungs, spleen …
- Model validation with methotrexate as positive drug control treatment
BENEFITS
- Preclinical studies in appropriate and relevant model of cutaneous and other lymphomas
- In vivo screening of therapeutic molecules in different compartments
- Compatible with imaging or monitoring methods of cutaneous lymphoma cells and other lymphomas
IP
This technology is protected by a patent application
Download the offer